The OAAH Family: Anti-Influenza Virus Lectins

Sato, Yoji; Hirayama, Makoto; Morimoto, Kanehisa; Hori, Kazuaki

doi:10.1007/978-1-0716-0430-4_59

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous lectins were identified to have antiviral properties, with a particular attention on lectins that target densely glycosylated RBD of enveloped viruses. The OAAH lectin exhibits robust anti-influenza virus activity through specific binding to high-mannose glycans present on the envelope glycoprotein hemagglutinin, effectively preventing viral entry into host cells [17]. Griffithsin (GRFT), a lectin isolated from the red algae, shows remarkable broad-spectrum antiviral activity.…”

Section: Introductionmentioning

confidence: 99%

<em>Microcystis viridis</em> NIES-102 Algae Lectin MVL Interacts with the COVID-19 Spike Protein RBDs via Protein-Protein Interaction

Wang,

Yang,

Shishido

et al. 2024

Preprint

View full text Add to dashboard Cite

The emergence of the coronavirus 19 (COVID-19) has posed a major challenge to healthcare systems worldwide, especially as COVID-19 mutations complicate the development of vaccines and antiviral drugs. Therefore, the search for natural products with broad anti-COVID-19 capabilities is an important option for the prevention and treatment of infectious diseases. Lectins, which are widely recognized as antiviral agents, could contribute to the development of anti-COVID-19 drugs. In this study, we evaluated the binding ability of a total of six lectins, including MVL from Microcystis viridis NIES-102, to the spike protein RBD of the original (wild) COVID-19 and it’s three mutants: alpha, delta, and omicron. As a result, two lectins, MVL from Microcystis viridis NIES-102 and jacalin from Artocarpus altilis, showed distinct binding ability to the RBDs of the four COVID-19 strains. The other lectins (DB1, ConA, PHA-M and CSL3) did not show any binding ability. Although the glycan specificities of the two lectins, MVL and Jacalin, were different, they showed the same affinity for the RBDs of the four COVID-19 strains, i.e., alpha &gt; delta &gt; original &gt; omicron. The verification of glycan-specific inhibition revealed that jacalin binds to RBDs by glycan-specific recognition, whereas MVL binds to RBDs by protein-protein interactions in addition to glycan-specific recognition.

show abstract

Section: Introductionmentioning

confidence: 99%

<em>Microcystis viridis</em> NIES-102 Algae Lectin MVL Interacts with the COVID-19 Spike Protein RBDs via Protein-Protein Interaction

Wang,

Yang,

Shishido

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Many lectins with antiviral properties have been identified, particularly those that target the densely glycosylated RBD of enveloped viruses. The Oscillatoria agardhii (Cyanobacteria) agglutinin homologue (OAAH) lectin family exhibits robust anti-influenza virus activity through specific binding to high-mannose glycans present on the envelope glycoprotein hemagglutinin, effectively preventing viral entry into host cells [ 17 ]. Griffithsin (GRFT), a lectin isolated from the red alga Griffithsia , shows remarkable broad-spectrum antiviral activity.…”

Section: Introductionmentioning

confidence: 99%

Microcystis viridis NIES-102 Cyanobacteria Lectin (MVL) Interacts with SARS-CoV-2 Spike Protein Receptor Binding Domains (RBDs) via Protein–Protein Interaction

Wang,

Yang,

Shishido

et al. 2024

IJMS

View full text Add to dashboard Cite

The emergence of coronavirus disease 2019 (COVID-19) posed a major challenge to healthcare systems worldwide, especially as mutations in the culprit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) complicated the development of vaccines and antiviral drugs. Therefore, the search for natural products with broad anti-SARS-CoV-2 capabilities is an important option for the prevention and treatment of similar infectious diseases. Lectins, which are widely recognized as antiviral agents, could contribute to the development of anti-SARS-CoV-2 drugs. This study evaluated the binding affinity of six lectins (including the cyanobacterial lectin from Microcystis viridis NIES-102 (MVL), and Jacalin, a lectin from the breadfruit, Artocarpus altilis) to the receptor binding domain (RBD) of the spike protein on the original (wild) SARS-CoV-2 and three of its mutants: Alpha, Delta, and Omicron. MVL and Jacalin showed distinct binding affinity to the RBDs of the four SARS-CoV-2 strains. The remaining four lectins (DB1, ConA, PHA-M and CSL3) showed no such binding affinity. Although the glycan specificities of MVL and Jacalin were different, they showed the same affinity for the spike protein RBDs of the four SARS-CoV-2 strains, in the order of effectiveness Alpha > Delta > original > Omicron. The verification of glycan-specific inhibition revealed that both lectins bind to RBDs by glycan-specific recognition, but, in addition, MVL binds to RBDs through protein–protein interactions.

show abstract

Cyanobacteria and their metabolites - can they be helpful in the fight against pathogenic microbes?

Grabowski,

Wiśniewska,

Żabińska

et al. 2024

Blue Biotechnology

View full text Add to dashboard Cite

Natural ecosystems are a rich source of compounds that can be considered as drugs to combat viral and bacterial infections. Cyanobacteria play a key role in the search for these compounds. These microorganisms, besides their well-known cytotoxicity to humans, are also a rich reservoir of metabolites with antiviral and antibacterial activities. These compounds are extremely diverse in their chemical structures. Moreover, recent reports have shown that Cyanobacteria can be used as platforms for the synthesis of antibacterial molecules such as gold and silver nanoparticles. In this review, we summarize and discuss recent reports on antiviral significance of these metabolites against the most relevant viruses, such as Human Immunodeficiency Virus (HIV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Herpes Simplex Virus (HSV), and Influenza Virus. We also focus on the effects of cyanobacterial metabolites against Gram-positive bacteria, including Staphylococcus aureus, as well as Gram-negative bacteria, including those from the ESKAPE group of pathogens. It is outlined what future research on the isolation of cyanobacterial metabolites should focus on to improve the effectiveness of this process and lead to the commercialization of widely available drugs for the pharmaceutical market.

show abstract

The OAAH Family: Anti-Influenza Virus Lectins

Cited by 3 publications

References 17 publications

<em>Microcystis viridis</em> NIES-102 Algae Lectin MVL Interacts with the COVID-19 Spike Protein RBDs via Protein-Protein Interaction

<em>Microcystis viridis</em> NIES-102 Algae Lectin MVL Interacts with the COVID-19 Spike Protein RBDs via Protein-Protein Interaction

Microcystis viridis NIES-102 Cyanobacteria Lectin (MVL) Interacts with SARS-CoV-2 Spike Protein Receptor Binding Domains (RBDs) via Protein–Protein Interaction

Cyanobacteria and their metabolites - can they be helpful in the fight against pathogenic microbes?

Contact Info

Product

Resources

About